Hepatitis B is different from other diseases in that you cannot judge whether you should be treated based on your symptoms alone. It is clinically found that a considerable number of hepatitis B virus carriers have not been monitored for hepatitis activity, but the hepatitis B virus damages the body quietly, so we often say that the hepatitis B virus is a latent hidden killer in the body, and most patients with chronic hepatitis do not have symptoms when their transaminases are mildly elevated. Some patients with chronic hepatitis B who should be treated mistakenly believe that antiviral therapy is irrelevant and that liver function abnormalities can be treated with liver-protective and enzyme-lowering drugs. In fact, hepatoprotective drugs can only temporarily protect the liver and improve liver function, but have no substantial effect on the hepatitis B virus, the fundamental treatment is antiviral therapy, because liver function damage is caused by the hepatitis B virus. Therefore, for patients with chronic hepatitis B, the long-term solution is antiviral treatment to truly protect the safety of the liver. The reason why there are 20-30 million patients with chronic active hepatitis and cirrhosis in China is the result of the fact that most patients do not receive antiviral treatment systematically. The latest statistics show that the chance of cirrhosis and liver cancer in the antiviral population is greatly reduced compared to the non-antiviral population!